Azafaros is a clinical-stage biotech company addressing rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat. Our focus is on developing disease-modifying therapies for patients with, among others, GM1 and GM2 gangliosidoses, and Niemann-Pick Type C disease.
Some insights
We are a team of biotech experts from a wide range of pharmaceutical industry backgrounds and with many years' experience in rare diseases. Our core strengths are achieving success in all stages of drug development and working closely with experts, patient advocacy groups and investors.